Publications
Daratumumab for refractory posttransplant autoimmune hemolytic anemia: An option beyond the obvious
Sreedhar Jayakrishnan Cherulil, Kesavan Melarcode Ramanan, Sudeep Vaniyath Autoimmune Cytopenia (AIC) is a complication that occurs in 2-6% of the post-transplant paediatric population. It is a significant cause of morbidity and a therapeutic challenge. The first line treatment is often corticosteroids, and Rituximab is used in the second line. Refractoriness to several lines of treatment is an often-encountered clinical scenario, here we would like to highlight the use of Daratumumab a novel anti CD 38 monoclonal antibody to treat post-transplant AIC. We report on the use of Daratumumab in combination with the conventional treatment with Rituximab and corticosteroids in a case of severe life threatening AIHA in a one-year-old child, who was suffering from TB-NK SCID, and had undergone post haploidentical stem cell transplantation.
